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The cholesterol dependent cytolysins (CDCs) are produced bymany
species from the Clostridium, Streptococcus, Listeria, Arcanobacterium,
Gardnerella, Bacillus and Lactobacillus genera. It is likely that additional
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Fig. 1.Molecular structure of Clostridium perfringens perfringolysin O. Shown is a ribbon
representation of the PFO crystal structure (PDB ID: 1PFO) [32]. Speciﬁc features of
the structure are designated as D1–D4, domains 1–4; TMH1 and TMH2 (orange),
transmembrane hairpins 1 and 2; β1, β4 and β5, β-strands 1, 4 and 5; α1, α-strand 1;
L1–L3, loops L1–L3. The double glycine motif is shown as purple space ﬁlled atoms. All
structures were generated using VMD [126].
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one of the most widely disseminated toxin genes known, suggesting
that many bacterial species ﬁnd it useful to introduce large pores in
cholesterol containing eukaryotic membranes. How these bacterial
pathogens use these toxins to establish and/or contribute to the
progression of an infection has been studied in only a handful of
organisms. It is clear, however, that these pathogens use the CDCs in far
more sophisticated ways than as simple cell lytic agents [1–4]. Many
studies have shown that the CDCs can induce various cellular effects,
usually at levels that do not lyse a cell [5–20], but the contribution of
these effects to disease progression remains less well understood. Some
disease causing pathogens express CDCs that lack the ability to form a
pore [21,22], which suggests that there may be functions of the CDCs
other than pore formation that can contribute to disease.
The pore formingmechanism of these toxins has been the object of
intense scrutiny for the past 20 years, which has provided signiﬁcant
insights into their pore forming mechanism. The CDCs exhibit several
hallmark features that include a complete dependence of their pore-
formingmechanism on the presence of membrane cholesterol and the
formation of extraordinarily large membrane pore complexes. The
study of the CDC pore complex has focused on understanding how
these soluble, monomeric proteins assemble into a large membrane
spanning pore complex. The subject of this review will be conﬁned to
providing a description of the assembly of the CDC pore complex. As
will be discussed below the study of the CDC pore formingmechanism
has revealed new paradigms in the assembly of a membrane pore
complex as well as providing insight into themechanism of other pore
forming proteins.
2. The CDC structure
2.1. The CDC primary structure
The ﬁrst primary structure of a CDC was reported in 1987 by
Walker et al. [23] for the Streptococcus pneumoniae CDC pneumolysin
(PLY), which was followed shortly thereafter by the primary structure
for the S. pyogenes streptolysin O (SLO) structure [24]. Since that time
the primary structures of over 25 different CDCs have been reported
in GenBank. These structures revealed that most CDCs are secreted as
soluble monomers from the bacterial cell using a typical type II signal
peptide. PLY is an exception to this rule since it lacks a signal peptide:
how PLY is released from S. pneumonia remains unclear. An early
study [25] suggested that it was released by cell lysis whereas more
recent studies suggest that release is not associated with cell lysis
but may be via a currently unidentiﬁed transport system [26,27].
Ultimately, the CDCs are released into the extracellular milieu as
soluble monomers that eventually bind to and form a large pore
complex in cholesterol containing membranes. The mass of the
secreted CDCs range from about 50 to 72 kD. The core structure
responsible for pore formation is about 50 kD: several CDCs, however,
exhibit amino terminal peptide extensions that range from about
a dozen amino acids to a 150 residue fucose binding lectin [28].
The function of these amino terminal extensions is generally poorly
understood. A short amino terminal peptide extension in the Listeria
monocytogenes CDC, listeriolysin O (LLO), appears to inﬂuence its
stability [29,30]. Another short peptide extension found at the amino
terminus of SLO appears to contribute to the SLO-mediated transport
of another protein across the membrane of a eukaryotic cell [4,31].
The amino terminal fucose binding lectin of the Streptococcus mitis
lectinolysin (LLY) appears to modulate its cytolytic activity, but how
it does so is not known [28].
The primary structures of the CDC family show a high degree of
conservation (40–70% identity). A highly conserved structural motif
of 11 residues (ECTGLAWEWWR) near the carboxy terminus is a
signature motif for the CDCs. This motif, which is termed the un-
decapeptide or tryptophan rich motif, contains the only cysteineresidue normally found in the secreted form of the CDCs and typically
contains 3 tryptophans. As will be apparent from this review it's
role in the pore forming mechanism has yet to be established un-
ambiguously. The primary structure of the secreted form of the CDCs
is remarkably hydrophilic with no obvious hydrophobic regions that
could be potential transmembrane regions.
2.2. The CDC crystal structure
The ﬁrst crystal structure of the soluble secreted form of a CDC
was solved in 1997 by Rossjohn et al. [32]. They crystallized and
solved the structure of the secreted form of the CDC from Clostridium
perfringens, perfringolysin O (PFO). In retrospect, the choice of PFO
for crystallization trials was somewhat fortuitous, as the structures of
the other three most well studied CDCs at that time, SLO, listeriolysin
O (LLO) and PLY, have yet to be solved 14 years later. Other CDCs
structures have been solved, however, and include Streptococcus
intermedius intermedilysin (ILY) [33], Bacillus anthracis anthrolysin
O (ALO) [34] and most recently Streptococcus suis suilysin (SLY) [35].
The structure of PFO (Fig. 1) revealed an elongated four-domain
protein that is rich in β-sheet. The structures of the other CDCs
mentioned above are highly similar to that of PFO with only small
differences in their overall shape. Initially, we proposed that the
domain 4 undecapeptide signature motif of PFO acted as a hydro-
phobic dagger to penetrate the membrane and form the pore [32].
This model of pore formation was based on the previous observation
by Nakamura et al. [36] showing that the tryptophans of the un-
decapeptide entered the membrane. As described below, however,
even though the undecapeptide enters the membrane it does not
directly contribute to the formation of the membrane pore.
The crystal structure of PFO was an important discovery that was
critical to the subsequent elucidation of the pore forming mechanism
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biophysical and biochemical studies revealed signiﬁcant insights into
the remarkable structural transitions in the CDC monomer that are
required to form the pore.
3. A brief introduction to the CDC pore-forming mechanism
Before proceeding into the details of the pore forming mechanism
the reader will be provided a brief description of the general features
of the CDC pore forming mechanism as it relates to the PFO crystal
structure in Fig. 1.
Bacteria release CDCs as soluble monomers: typically by a type II
secretion pathway. The soluble monomers then bind to the eukary-
otic cell surface via cholesterol, although a few CDCs have evolved
to use human CD59 as their receptor [37,38]. As described below
the CD59 binding CDCs still require the presence of membrane
cholesterol to function [39–41]. The initial interaction of the
cholesterol binding CDC monomers with the cell surface is mediated
via the tip of domain 4 (Fig. 1) where the conserved undecapeptide
and loops L1–L3 have been shown to anchor the monomer to the
membrane [42,43]. The monomers are bound via the tip of domain 4
in an upright position that is perpendicular to the membrane [44,45].
Membrane binding initiates changes within the monomer structure
that leads to the formation of intermolecular contacts between
membrane-bound monomers [46]. A major transition that is
required for monomer–monomer contact is the rotation of the loop
comprised of β5 and α1 (Fig. 1) away from β4 of the domain 3 core
β-sheet. This action frees up the edge of β4 to pair with β1 of another
monomer [46]. The monomers continue to extend the oligomeric
structure until a ring shaped structure is achieved. This structure
is termed as the prepore complex and is deﬁned as the completed
ring complex that has not yet inserted its β-barrel pore. The prepore
state likely has several intermediate states that are currently deﬁned
by whether the ring complex is SDS-sensitive or resistant [47–49].
During assembly of the ring-shaped prepore complex two trans-
membrane β-hairpins (TMHs) from each monomer are derived from
the two domain 3 α-helical bundles (Fig. 1) and contribute to the
formation of the large β-barrel structure [50,51]. To assemble the
PFO pore approximately 36 monomers form a completed ring com-
plex, although this number can vary by a few monomers either
way [45]. Therefore, PFO assembles and coordinates the insertion of
a β-barrel structure that contains approximately 144 membrane-
spanning β-strands or 72 β-hairpins, which results in the formation
of a pore with a diameter of 250–300 Å. The CDC pore is currently
the largest known toxin pore.
4. Membrane recognition
4.1. Characteristics of lipid, sterol and membrane structure that inﬂuence
CDC binding
Most CDCs bind to membranes by using the cholesterol as their
receptor. One of the ﬁrst hallmark traits to be identiﬁed for the CDCs
was the ability of added cholesterol to inhibit the hemolytic activity
of these toxins, presumably by occupying a receptor binding site
(reviewed in [52]). The interaction of these toxins with cholesterol
and its role as the receptor have been difﬁcult to elucidate due to the
insoluble nature of cholesterol and the inability to generate cocrystal
structures of the CDCs with cholesterol. Early studies by Prigent et al.
[53] showed that an intact 3-β-hydroxyl group, an aliphatic sidechain
of appropriate length at carbon 17 of the D ring, a methyl group at
carbon 20 and an intact B ring were important to its recognition by
CDCs. Sterols with a 3-α-hydroxl or modiﬁcations of the 3-β-hydroxyl
were not bound by these CDCs, thus demonstrating that recognition
was restricted to the 3-β-hydroxyl. Other minor changes in the ring
structure, such as the saturation state of the B ring, did not affecttheir ability to inhibit the hemolytic activity of the CDCs. These studies
primarily determined the structures of puriﬁed sterols required to
bind and inhibit the CDCs, but as described below the lipid envi-
ronment of intact membranes also plays a major role in whether
cholesterol will be recognized and bound by the CDCs. In a subsequent
study Alouf and coworkers also showed that the stoichiometry of the
interaction between the CDCs and cholesterol was 1:1 [54], suggesting
a single cholesterol binding site was present on the toxins.
Ohno-Iwashita and colleagues have extensively studied the inter-
action of the CDC from Clostridium perfringens, PFO [36,55–67]
with membranes and cholesterol. One of their ﬁrst observations was
that chemical modiﬁcation of the single cysteine in the conserved
undecapeptide of PFO caused a signiﬁcant loss of hemolytic activity
[55]. The loss in activity resulted from an altered membrane binding
afﬁnity thatwas associatedwith a reversible conformational change in
PFO. This was the ﬁrst evidence that suggested the undecapeptidewas
involved in the interaction of PFOwith themembrane. They also found
that PFO exhibited biphasic binding to cholesterol-rich membranes:
high and low afﬁnity binding was observed [68]. Since both high
and low afﬁnity binding sites were dependent on cholesterol, they
suggested that cholesterol exhibited a heterogeneous distribution in
membranes and that only a fraction of the cholesterol was easily
accessible and formed the high afﬁnity binding sites. This insight
was prescient as Heuck et al. [69] subsequently studied binding to
cholesterol containing liposomes. Although they did not observe a
biphasic binding they did ﬁnd that binding of PFO to cholesterol-rich
liposomes exhibits a sharp transition from undetectable binding at
40 mol% total membrane cholesterol to maximal binding at 55 mol%.
Hence, not all cholesterol at the surface of the membrane forms a
suitable receptor for PFO (andprobablymost CDCs). Typically, efﬁcient
binding of CDCs requires N30 mol% of the total membrane lipid to be
cholesterol [69–71], therefore, only a fraction of the total membrane
cholesterol likely serves as a suitable receptor.
The studies of Flanagan et al. [70] andNelson et al. [72] showed that
the accessibility of cholesterol to PFO is dependent on the phospho-
lipid structure: lipids that could pack tightly with cholesterol, such as
those with unsaturated acyl chains, tended to decrease binding to
cholesterol. Lipids that did not pack tightly with cholesterol, such as
those with unsaturated acyl chains, shifted the half maximal binding
to lower cholesterol levels. They also found that the addition of
epicholesterol, which contains a 3-α-hydroxyl group and is not bound
by PFO, increased binding of PFO to the membrane. This apparently
resulted from the displacement of cholesterol by epicholesterol from
its interaction with the lipids, thus freeing up cholesterol from its
association with lipid and increasing its availability to PFO. These
studies suggested that when the cholesterol concentration exceeded
the associative capacity of the lipid it was free to be recognized and
bound by PFO. The phospholipid headgroup size also inﬂuences the
availability of cholesterol at the membrane surface. Zitzer et al. [73]
have shown for SLO that lipids with smaller headgroups increase the
binding of SLO to membranes. In retrospect these observations make
sense since tightly packed lipid–sterol mixtures or mixtures contain-
ing lipids with larger headgroups are more likely to sterically occlude
the relatively small 3-β-hydroxyl of cholesterol thereby restricting
access of the CDC cholesterol binding motif (described below) to the
cholesterol 3-β-hydroxy headgroup.
It was also shown by Waheed et al. [66] that PFO preferentially
partitioned into the detergent-resistant membrane (DRM) fraction of
cells. Since microdomain structure is often rich in cholesterol it made
sense that PFO partitioned with the detergent resistant membrane
fraction. This observation, however, has been complicated by the
recent studies of Flanagan et al. [70]. They showed that increasing the
molar fraction of sphingomyelin, a constituent of rafts, in liposomes
decreased PFO binding to cholesterol. Sphingomyelin contains
unsaturated acyl chains and would tend to pack more tightly with
cholesterol. Since sphingomyelin is concentrated in DRMs these data
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Fig. 2. The structure of the undecapeptide motif and location of the CRM. Shown in
panel A is an overlay of domain 4 structures from Clostridium perfringens PFO (red),
Streptococcus suis SLY (PDB ID: 3HVN) [35] (yellow), Bacillus anthracis ALO (PDB ID:
3CQF) [34] (cyan) and Streptococcus intermedius ILY (PDB ID: 1S3R) [33] (blue). Shown
in B is the location of the cholesterol recognition/binding motif of the same CDCs as in
panel A (colors assignments are the same as in panel A).
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cholesterol-rich microdomains in natural membranes. More prob-
lematic, however, is the observation by Flanagan et al. that the PFO
oligomer alone exhibited a propensity to partition into the detergent
resistant fraction, therefore detergent fractionation cannot be reliably
used to determine if CDC complexes are associated with DRMs.
4.2. The CDC cholesterol recognition/binding motif (CRM)
The identiﬁcation of the CDC cholesterol recognition/binding
motif (CRM) has been an elusive problem for nearly three decades.
Many studies have shown that regions and residues in domain 4
of the CDC structure affect binding of the CDCs to the membrane
[36,55,62,65,67,74–76]. More recent studies have narrowed the
regions of domain 4 that interact with the membrane to the un-
decapeptide [43] and three loops (L1–L3) at the tip of domain 4 [42]
(Fig. 1). The rest of domain 4 is surrounded by water throughout the
assembly of the oligomeric pore complex [42]. Investigators have
generally accepted that the conserved undecapeptide motif contrib-
uted to cholesterol recognition. This was not an unreasonable theory
since the undecapeptide is highly conserved in the CDCs and studies
showed that one or more of the tryptophans in the undecapeptide
inserted into the bilayer [36], although not deeply [43]. Further-
more, Ohno-iwashita and colleagues [55,74] showed that chemical
modiﬁcation of the undecapeptide cysteine of PFO decreased binding,
although the modiﬁcation also induced a conformation change in
the structure of PFO, which could have affected binding indirectly.
Furthermore, alanine mutants within nearly every residue of the PFO
undecapeptide resulted in signiﬁcant perturbations in its hemolytic
activity and membrane binding [33]. Jacobs, et al. showed that
monoclonal antibodies to the undecapeptide inhibit binding [65],
however a large antibody bound at the tip of domain 4 would likely
disrupt any interaction mediated by this region with the membrane.
In total, these studies provided compelling evidence that the un-
decapeptide was the cholesterol-binding motif.
A series of relatively recent studies, however, suggested the
CRM resided within loops L1–L3 rather than the undecapeptide.
Soltani et al. [77,78] showed that they could uncouple the cholesterol-
dependent membrane insertion of the undecapeptide from the
cholesterol binding function of the CDCs, which suggested that the
CRM resided somewhere in loops L1–L3. Furthermore, the solution of
the crystal structures for other cholesterol binding CDCs showed that
the undecapeptide 3-dimensional structure in the crystal structures
of PFO, ILY, Bacillus anthracis anthrolysin O (ALO) and more recently
Streptococcus suis suilysin (SLY) adopt different structures (Fig. 2A),
which makes it difﬁcult to envision how they could recognize and
bind to a common receptor motif. These differences were not due to
crystal packing forces, but appear to be the result of differences in
speciﬁc sidechain interactions between conserved residues of the
undecapeptide and residues outside of the undecapeptide.
Farrand et al. [40] performed an alanine scan of the residues in
loops L1–L3 of PFO and determined that two mutations affected
hemolytic activity and binding to a greater extent than any other
residues in these loops. These residues are a threonine–leucine pair
(residues 490 and 491 of PFO) in loop L1 (Fig. 2B). These residues are
conserved in all known CDCs, even those that use human CD59 rather
than cholesterol as a receptor. As described below (Section 4.3) the
Thr–Leu CRM is also necessary to the cytolytic mechanism of the
human CD59 binding CDCs, although it does not function as a
receptor-binding motif in those proteins. Farrand et al. showed that
alanine and/or glycine substitutions for both residues in PFO, SLO
and PLY abolished binding to cholesterol rich liposomes, puriﬁed
cholesterol and the cholesterol rich membranes of eukaryotic cells.
They also showed that conservative substitutions for either residue
signiﬁcantly decreased binding and activity: substitution of serine for
Thr-490 and either valine or isoleucine for the leucine-491 of PFOnearly completely abolished binding. Therefore, even the most con-
servative substitutions are not well tolerated.
The cholesterol recognition/binding motif of the CDCs is surpris-
ingly simple and inviolable. Neither trait should be unexpected since
the headgroup of cholesterol is also comparatively simple when
compared to other receptor molecules. A complex binding site on
the CDCs for cholesterol would not be expected since cholesterol has a
relatively limited headgroup exposed at the surface if the membrane.
Only the 3-β-hydroxyl and possibly portions of the A ring of cho-
lesterol are exposed at the surface. One possible binding mechanism
is that the leucine inserts into the bilayer and interacts with the A ring
and the threonine forms a hydrogen bond with the 3-β-hydroxyl
group. The leucine may constantly sample the membrane surface
and only upon the correct orientation with the cholesterol headgroup
does the threonine lock in the interaction by forming a hydrogen
bond with the 3-β-hydroxyl. This interaction is also stereo-speciﬁc, as
the CDCs do not interact with epicholesterol, which has a 3-α-
hydroxyl.
Once the Thr–Leu pair establishes an interaction with the
membrane cholesterol the residues within loops 2 and 3 insert into
the bilayer and ﬁrmly anchor the monomer to the membrane [40].
At some point, perhaps coincident with insertion of the L2–L3 loops,
portions of the undecapeptide also enter the membrane. The un-
decapeptide is located near the Thr–Leu pair and so many of the
previously described undecapeptide mutations [33,55,62] may have
altered its structure in a way that interfered with the interaction of
the CRM with cholesterol and/or membrane insertion of the loops L2
and L3.
4.3. Human CD59 binding CDCs
Streptococcus intermedius produces ILY, which was shown by
Nagamune et al. [79] to lyse only human erythrocytes: nonhuman
primate erythrocytes were 100-fold less sensitive to ILY whereas
all animal erythrocytes tested were resistant to lysis. They further
showed that the hemolytic activity on human erythrocytes could
be decreased by pretreatment of the erythrocytes with a protease,
suggesting that a protein contributed to ILY binding. This observation
was in stark contrast to what was generally understood about CDCs,
which were thought to use only cholesterol as their receptor. Nearly
a decade after its discovery the basis for the highly selective behavior
of the ILY cytolytic activity was revealed by the studies of Giddings
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Since then two more CDCs have been discovered that also use human
CD59 as their receptor, Gardnerella vaginalis vaginolysin (VLY) [38]
and Streptococcus mitis lectinolysin (LLY) [80]. Interestingly, CD59 is
a GPI-anchored surface protein and is an inhibitor of the complement
membrane attack complex (MAC) [81,82]. CD59 protects host cells
from complement-mediated lysis during times of bacterial infection
when complement is activated. It does so by binding to complement
proteins C8α and C9, which are two proteins of the complement
system that are necessary for the formation of the complement
membrane attack complex (MAC) pore (reviewed in [83]). CD59 is
homologously restricted [82]: i.e., it only functions to inhibit the host's
complement and not that of other species. The fact that ILY only
bound and lysed human cells was shown to result from its ability to
bind to the site on human CD59 that also endowed it with its species-
speciﬁc inhibition of the complement MAC [37,82].
The ILY binding site for CD59 was recently mapped by Wickham
et al. [80]. The CD59 binding site is located in domain 4 and
contains a signature motif of YXYX14RS that is found in VLY and
was used to identify LLY as a member of the CD59 binding family of
CDCs. This motif is located on the outer surface of the ring on the
side of domain 4 that is predicted to face away from the lumen of
the pore. As indicated above, the normal cellular function of CD59
is to inhibit the assembly of the MAC pore complex by binding to
complement proteins C8α and C9. The ILY consensus sequence is
not present in C8α or C9. More details on the interaction of ILY
and the complement proteins with CD59 are described below in
Section 7.2, as the CDCs and C8α and C9 may share mechanistic and
evolutionary relationships.
Formost CDCs binding to the cholesterol receptor initiates changes
in the monomer structure that lead to the formation of the pore
complex. In ILY this function has been transferred to the CD59 binding
site [77]. Binding to human CD59 rather than cholesterol initiates
these same structural transitions [77]. Binding to CD59 still triggers
these changes in cholesterol-depleted membranes, but without cho-
lesterol the pore itself does not form [41]. Therefore membrane
cholesterol remains important to the mechanism of ILY, even though
it has switched receptors from cholesterol to CD59.Why then does ILY
still require cholesterol for its pore forming activity and why did it
retain the CRM if its receptor function was replaced by CD59?
These questions were addressed in two studies: the ﬁrst by
Lachapelle et al. [39] and the second by Farrand et al. [40]. Lachapelle
et al. [39] ﬁrst showed that ILY disengaged from CD59 upon prepore
to pore conversion. This study raised the question, however, that if
ILY disengaged from its receptor how did it maintain contact with the
membrane so that it could insert its β-barrel pore? Farrand et al. [40]
subsequently showed that ILY containing a CRM knockout remained
bound to the membrane via its interaction with CD59 prior to con-
version of the prepore to pore, but upon conversion of the prepore to
the pore the oligomeric complex formed by the CRM knockout lost
contact with the membrane as it disengaged from CD59. Therefore,
interaction between ILY and CD59 performs two important func-
tions: (1) it initiates the structural changes that are necessary for
pore formation and (2) it positions the CRM so that it can bind to
cholesterol and initiate the insertion of loops L1–L3 into the mem-
brane. The additional membrane anchor provided by the cholesterol-
dependent insertion of loops L1–L3 is necessary to keep the prepore
complex attached to the membrane as it disengages from CD59
during the critical prepore to pore transition. If the CRM is knocked
out then the pore complex detaches from the membrane as it
disengages from CD59 and tries to insert the β-barrel pore [40].
Why does ILY disengage from CD59 during its transition to the
pore complex? It appears that the adoption of CD59 by ILY as its
receptor did not occur without consequences. The disengagement of
ILY from CD59 is apparently necessary for the transition from the
prepore to pore. Wickham et al. [80] showed that mutations in eitherCD59 or ILY that increased the binding afﬁnity of the interaction
decreased the rate of pore formation. Their studies strongly suggested
that the increased afﬁnity of the ILY-CD59 interaction slowed the rate
at which ILY disengaged from CD59, therefore slowing the rate of the
prepore to pore transition [80]. This predicted that if the binding
afﬁnity was sufﬁciently high it would prevent the prepore to pore
transition. Therefore the binding afﬁnity between ILY and CD59 must
be balanced such that it is not too high, which would slow the rate of
pore formation, but not so low as to affect the on-rate of binding,
which would also slow pore formation.
It is also interesting to note that in the absence of the CRM the
residues of loops 2 and 3 do not independently insert into the
membrane and anchor ILY to the membrane surface. The CRM of ILY
cannot bind it to the cell surface if CD59 is absent [37], which suggests
that binding to CD59 must orient the CRM near the membrane so that
it can interact with cholesterol. Presumably binding to CD59 also
brings loops 2 and 3 near the membrane since they are juxtaposed to
the CRM (Fig. 2B). Yet, in the absence of the CRM these hydrophobic
loops alone cannot insert into the membrane and anchor ILY. There-
fore the interaction of the CRM with cholesterol is a necessary pre-
requisite for the insertion of these loops.
5. Formation of the prepore complex
The prepore complex is deﬁned as a completed oligomeric complex
on the verge of inserting itsβ-barrel pore.Whether a prepore statewas
an assembly intermediate of the large CDC oligomeric pore complex
was initially an issue of debate. Palmer et al. [84] proposed a model of
pore assembly in which a CDC dimer inserted in the membrane
followed by the addition of monomers that enlarged the pore from a
small pore to a large pore. They suggested that insertion of such a large
β-barrel pore from a prepore complex was energetically unfavorable.
In fact, the insertion of a naked amphipathic β-hairpin into a
membrane is energetically unfavorable [85]. The membrane core
lacks hydrogen bond donors or acceptors to which the polar atoms of
the β-hairpin polypeptide backbone could hydrogen bond, therefore
signiﬁcantly raising the energetic cost of positioning the hairpins
within the bilayer. Formation of a partial or wholly formed pre-β-
barrel would be more energetically favorable for membrane insertion.
It was subsequently shown in two studies by Shepard et al. [49] and
Hotze et al. [48] that PFO formed a large prepore complex and that this
complex then converted to the pore complex. The formation of the
prepore complex may facilitate the organization of the large β-barrel
pore prior to its insertion by allowing the formation of some or all
of the interstrand hydrogen bonds between the transmembrane β-
hairpins (TMHs). The fact that insertion of the β-barrel after prepore
formation was favorable was shown by the work of Hotze et al. [48].
They engineered a disulﬁde between TMH1 and domain 2 (Fig. 1) that
prevented the extension of TMH1 and allowed PFO to form a SDS-
resistant prepore on membranes. If the disulﬁde was then reduced
after oligomerizationwas completed the insertion of the β-barrel pore
was rapid. These studies showed that (1) the rate limiting step in
the formation of the pore complex is the assembly of the oligomeric
prepore complex and (2) that once it is completed the insertion of the
β-barrel pore is rapid.
More than one prepore state has been identiﬁed in PFO
suggesting that monomer–monomer interactions proceed through
various intermediate states during the assembly of an SDS-resistant
prepore complex. Membrane binding primes the monomers for
oligomerization: once a monomer has bound to the membrane its
structure changes to allow monomer–monomer interactions. These
interactions do not occur in solution, even at the high concentrations
of protein required for crystallization [86]. The extent to which the
structure of the CDC monomer changes upon binding, however, is
incompletely understood. Ramachandran et al. [46] have shown that
the disruption of the edge-on interaction of β5 with β4 in domain 3
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the edge of β4 to then pair and form interstrand backbone hydrogen
bonds with β1 of another monomer. In addition to the formation of
interstrand hydrogen bonds an intermolecular π-stacking interaction
is also formed between a tyrosine in β1 and a phenylalanine in β4
(Tyr-181 and Phe-318 in PFO). This interaction is critical to the
formation of a SDS-resistant prepore complex; loss of either residue,
or moving one of these aromatics out of register on either strand
results in the formation of an SDS-sensitive prepore complex that
cannot form a pore [46,47]. It was suggested [46] that the π-stacking
interaction locks β1 and β4 into the correct in-register pairing of
their backbone hydrogen bonds. Although the great majority of
CDCs maintain these two residues, the π-stacking interaction is not
present in the CD59 binding CDCs and is also missing in the cho-
lesterol binding CDCs pneumolysin, Lactobacillus iners inerolysin and
Arcanobacterium pyogenes pyolysin. Regardless of the function of the
π-stacking interaction in those CDCs that maintain this aromatic pair
it is obvious that some CDCs have solved this problem in another
way.
Monomer–monomer contact may also help drive some of the
domain 3 structural transitions necessary for pore formation. As
indicated above, elimination of one of the aromatics that participate in
the interstrand π-stacking interaction traps PFO in a SDS-sensitive
prepore complex. If mixed with functional PFO this π-stacking mutant
can be driven to form an SDS-resistant oligomeric complex and to
insert its TMHs into the membrane [47]. This presumably occurs
because the functional PFO monomers form cooperative interactions
with the mutant PFO molecules that induce these monomers to
undergo the necessary structural transitions to form a pore. Hence,
membrane binding may induce some structural changes that prepare
the CDC for oligomerization, but monomer–monomer interactions
may propagate additional structural changes necessary for pore
formation.
A second structurally important signature motif of the CDCs was
also revealed by these studies: the presence of a conserved Gly–
Gly pair (Gly-324 and 325 in PFO) that are located in the β-loop
between β4 and β5 (Fig. 1). Residues with sidechains cannot be
substituted for either glycine without blocking the disengagement
of β5 from β4 [46], which suggests that sidechains at this location
clash with other residues and prevent rotation of β5 away from β4.PFO
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Fig. 3. The crystal structures of MACPF family proteins showing a CDC domain 3 like struct
complement C8 (PDB ID: 3OJY) [120] and the Photorhabdus luminescens Plu-MACPF (PDB I
domain 3-like fold is highlighted. Shown in purple ribbon structure in each MACPF structure
red space ﬁlled atoms is the conserved twin glycine motif of each protein that is present atInterestingly, this motif is also positionally conserved within the
recently solved crystal structures of several membrane attack/per-
forin (MACPF) proteins (Fig. 3). The MACPF and CDC proteins lack
similarity at primary structure level, but the MACPF proteins
exhibit structural similarity with domain 3 of the CDCs (described
in Section 7 below) [87–90].
6. Formation of the β-barrel pore
6.1. The structure of the β-barrel pore
After solution of the PFO crystal structure one of the ﬁrst features
of the CDC mechanism to be revealed was the structure of the
membrane-spanning domain. Originally, we proposed that the
domain 4 undecapeptide acted as a hydrophobic dagger that plunged
into the membrane, which was based on the available data that
showed the undecapeptide tryptophans entered the bilayer [62].
Palmer et al. [91], however, identiﬁed three residues within domain
3 of streptolysin O that also appeared to also enter the membrane
and proposed the presence of a membrane spanning amphipathic
α-helix. Shortly thereafter Shepard et al. [51] and Shatursky et al.
[50] disproved both models by completely mapping the membrane
spanning regions of PFO using a combination of cysteine scanning
and ﬂuorescence spectroscopy. Two sets of α-helical bundles that
ﬂank the domain 3 core β-sheet, which extends from the domain 3
core β-strands 1–4 (Fig. 1), were identiﬁed that underwent a change
in secondary structure to form two amphipathic β-hairpins. Shatursky
et al. [50] further showed that these twin hairpins spanned the
bilayer. Since the PFO oligomeric complex is composed of about 36
monomers (some CDCs may contain more monomers) up to 144
amphipathic β-strands are positioned in the membrane to form the
CDC β-barrel pore.
The primary structure of the TMHs is some of the least conserved
primary structure of the CDCs, although they maintain the typical
amphipathic structure of a membrane spanning β-hairpin. Other than
the amphipathic nature of the TMHs, no other conserved features
are apparent in either TMH. Each TMH is approximately 30 residues
long or 15 residues per β-strand. A few residues are highly conserved
within each TMH between the CDCs, although no reason for their
conservation has been identiﬁed. Leu-207 and Phe-211 of PFO are the      C8
lement 
8
an) Plu-MACPF(Photorhabdus 
luminescens )
ure. The crystal structures of the MACPF proteins mouse perforin (PDB ID: 3NSJ) [88],
D: 2QP2) [89] are shown with that of PFO [32]. In each MACPF structure the PFO-like
is the structure analogous to the PFO α1-β5 loop that rotates away from β4. Shown in
the junction between β4 and β5, which is conserved in all known CDCs [46].
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be changed to cysteine with comparatively little loss in pore forming
activity [51]. Ala-293 in TMH2 is also highly conserved (96% identify)
among the CDCs. Substitution of Ala-293 with cysteine did not
signiﬁcantly affect its pore forming activity, however, the subsequent
modiﬁcation of the cysteine thiol with a ﬂuorescent probe decreased
the activity to less than 10% of native PFO suggesting that a bulky
group at this position is not tolerated [50].
6.2. The CDC oligomeric pore complex
CDCs are often seen to form a mixture of rings and incomplete, or
arc-shaped complexes by electron microscopy (EM) [49,92–94].
Whether these incomplete rings can insert a partial β-barrel remains
unknown: the available data suggests that they do not insert into
the membrane and may be artifacts of the EM process, dead end
complexes or simply a matter of partially inactive protein prepara-
tions. If incomplete rings inserted into the membrane with the same
probability as a complete ring then the likelihood of forming complete
rings would be comparatively low. It is possible that membrane
inserted fragments could associate to form a complete ring but they
would require, like a puzzle, pieces that would be just the right size to
assemble the ring. This type of assembly mechanism would be a
comparatively inefﬁcient method for assembling a ring, especially if
formation of a ring complex was necessary. A method of quantifying
the formation of the CDC prepore and pore complex was developed
by Shepard et al. [49]. They used SDS-agarose electrophoresis [49],
which separated the very large CDC pore complex from the monomer
and intermediates in the assembly process. They showed that the
only SDS-resistant form of the PFO oligomeric complex was a fairly
homogeneous high molecular weight species shown to be ring
complexes: intermediates in the assembly of the ring complex were
rare, even at early stages of assembly when they were stabilized
by crosslinking. Furthermore, Heuck et al. [43] have shown that at
limiting dilutions of PFO where, on average, a single pore is formed in
a liposomal membrane the release of low and high molecular weight
markers remains the same as observed at higher concentrations of
pores. Hence, the available data suggests that a very large complex,
which is presumably a complete ring, is the functional pore-forming
species.
6.3. CDC activation: disruption of the domain 2–3 interface
Disruption of the domain 2–3 interface is at the heart of the CDC
pore forming mechanism. This interface primarily exists between the
α-helical bundle that ultimately forms TMH1 and domain 2 (Fig. 1),
although regions of domain 1 also form some contacts with the
domain 3α-helical bundle. In order to unravel thisα-helical bundle to
extend and form TMH1 it must disengage from its interface with
domains 2 and 3. Before it was understood that these α-helical
bundles formed the TMHs Rossjohn et al. [32] had noted in the crystal
structure of the PFO monomer that this interface exhibited poor
complementarity, which was consistent with the fact that this
interface must be disrupted to extend TMH1.
How this interface is disrupted is incompletely understood. Heuck
et al. [69] showed that membrane insertion of the domain 4
undecapeptide was conformationally linked to the insertion of the
TMHs, demonstrating a link between structural changes in domain
3 that are necessary for insertion of the β-barrel and membrane
insertion of the domain 4 undecapeptide. Based on different crystal
forms of PFO Rossjohn et al. [95] showed that rotational torsion
between domains 1–3 and domain 4 broke several contacts at this
interface: presumably some torsion may be induced by binding of
PFO to the membrane. Whether binding alone can induce sufﬁcient
torsional stress to disrupt this interface and extend TMH1 remains
unknown. How this conformation signal is communicated from thetip of domain 4, which interacts with the membrane, to this interface
is also unknown. As indicated above in Section 5 monomer–monomer
contact is also important in driving some domain 3 structural changes
[47]. Hence, it is likely that a combination of membrane binding
and monomer–monomer contact may be important in driving this
transition.
6.4. Membrane insertion of the β-barrel pore
Shepard et al. [51] and Shatursky et al. [50] had clearly
demonstrated that both TMH1 and TMH2 crossed the bilayer, but
the length of the extended TMHs were calculated to be only long
enough to reach the surface of the bilayer, but not cross it. This
conundrum results from the fact that the bottom of domain 3 is
suspended about 40 Å above the membrane, which is approximately
the length of the extended hairpins. Therefore, how did the β-barrel
pore cross the membrane? Czajkowsky et al. [45] solved this problem
by using atomic forcemicroscopy tomeasure the height of the prepore
and pore complexes. They ﬁrst measured the height of a PFO mutant
that was trapped in the prepore state by an engineered disulﬁde
between domain 2 and the domain 3 α-helical bundle that inhibited
the complete disruption of the domain 2–3 interface [48]. The prepore
complexwas determined to extend about 113 Å above themembrane,
which closely corresponded to the length of themonomer from the tip
of domain 4 to the top of domain 1. Upon reduction of the disulﬁde,
which allowed the prepore complex to convert to the pore complex,
they showed that the pore complex extended only 73 Å above the
membrane. These data showed that insertion of the β-barrel was
associated with a 40 Å vertical collapse of the prepore complex, the
distance required to bring domain 3 sufﬁciently near the membrane
surface to allow the hairpins to extend across the bilayer. This was
conﬁrmed shortly thereafter by Ramachandran et al. [44] who used
Förster resonance energy transfer (FRET) based distance measure-
ments between ﬂuorescent probes within domains 1 and 3 in PFO and
the membrane surface. They showed that domains 1 and 3 moved
about 35 Å closer to the membrane when the prepore was unlocked
and allowed to convert to the pore complex.
Czajkowsky et al. [45] also proposed that once the domain 2–3
interface was disrupted that the domain 2 structure collapsed or
folded thereby allowing domains 1 and 3 to move towards the mem-
brane. Tilley et al. [96] later supported this scenario using cryoEM data
of the PLY pore, which they used to generate a 3D reconstruction of
the pore complex that was ﬁtted with the crystal structure of the PFO
monomer. Their data showed that the vertical collapse of the prepore
complex was associated with the appearance of a bulge on the outer
ring surface that was consistent with a folded domain 2 when ﬁtted
with the PFO crystal structure.
6.5. Regulation of the listeriolysin O pore forming activity by pH
The disruption of the domain 2–3 interface is also used to control
the pH dependent activity of one CDC, listeriolysin O (LLO), from
Listeria monocytogenes. For nearly 25 years it's been known that
the pore-forming activity of LLO was sensitive to pH: LLO exhibits
maximal activity at lower pH ranges (pH 5–6) and undetectable
activity at pH values of 7 or higher [97]. LLO was also shown to be
critical to the escape of L. monocytogenes from the vacuole into the
cytosol, where it replicated and could undergo cell-to-cell spread
without an extracellular phase, thereby protecting it from the
immune system (reviewed in [98–100]). It is important that LLO
cytolytic activity be tightly controlled: it must function at the low pH
of the endosome to effect escape of the bacterial cell into the
cytoplasm but must be switched off once escape has occurred to
prevent lysis of the host cell membrane. If the host cell membrane is
lysed it exposes the bacterial cells to the immune system, which
results in an avirulent phenotype [1,101–103]. The structural basis for
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assumed to be similar to other pH-sensitive toxins, such as diphtheria
toxin and anthrax toxin. These toxins are inactive and stable at
neutral pH, but upon being taken up into an endosome, which is
acidiﬁed by the vacuolar ATPase, the low pH triggers the structural
changes that allow them to insert into the membrane and translocate
their enzymatic fragment [104–110].
This mechanism, however, is not utilized by LLO to control for-
mation and insertion of its β-barrel pore. In contrast, acidic residues in
domain 3 act as a pH sensor and prematurely trigger the disruption of
the domain 2–3 interface in the soluble monomer at neutral pH above
temperatures of 30 °C [111]. The premature unfurling of the domain 3
α-helical bundles in the soluble monomers inactivates LLO and causes
it to aggregate in solution. The aggregation results from the exposure
of hydrophobic residues that are normally protected in the soluble
monomer, but which are exposed by the disruption of the domain 2–3
interface [111]. Disulﬁde locking TMH1 to domain 2 signiﬁcantly
decreased the rate of this inactivation, showing that it was the
disruption of the domain 2–3 interface that results in this inactivation.
These structural changes do not occur at acidic pH, which is found in
the vacuole where the LLO monomers remain stable and capable of
membrane binding and insertion of the β-barrel pore. Hence, LLO is
not pH activated, but is pH inactivated at neutral pH at temperatures
above 30 °C. This mechanism allows LLO to function in the acidic
environment of the vacuole where it is required to effect release of the
phagocytized bacterial cell, but then is inactivated to prevent lysis of
the host cell as the bacteria cell escapes into the neutral environment
of the cytoplasm.
The LLO pH sensor is composed of a triad of domain 3 acidic
residues, Asp-208, Asp-320 and Glu-247. They are located in the
domain 3 core β-sheet near the domain 2–3 interface and their
carboxylates are predicted to point in at each other [111]. The close
proximity of carboxylates is known to increase the pKa of carboxyl-
ates to pH 6–8 [112–115], therefore at acidic pH these residues are
mostly protonated and domain 3 remains stable. However, as the
pH increases the carboxylates deprotonate and charge repulsion
between the carboxylate groups is predicted to destabilize the domain
2–3 interface and cause its disruption, which inactivates the soluble
monomer. Replacement of these LLO residues by those present in
PFO, a CDC that is stable at acidic and neutral pH, eliminated the pH
sensitive nature of LLO [111].
Therefore, at the acidic pH of the vacuole the LLO monomers
remain stable and can bind to the membrane and follow the normal
mechanism of activation to form a pore, thus facilitating the escape of
the bacterial cell in to the cytoplasm. Remaining or newly synthesized
soluble LLO monomers that are present after escape of L. mono-
cytogenes from the vacuole would be rapidly inactivated in the neutral
pH environment of the cytoplasm at 37 °C. Hence, in LLO domain
3 plays a dual role, at acidic pH it functions normally to extend the
TMHs and form the β-barrel pore after membrane binding, but at
neutral pH it causes the premature unfurling of the α-helical bundles
in soluble monomers, which results in the inactivation of LLO thereby
preventing the unwanted lysis of the host cell.
7. The membrane attack complex/perforin family proteins
7.1. Structural similarities between the CDC and MACPF protein families
suggest a pore forming mechanism for the MACPF proteins
The pore forming mechanism(s) of the complement membrane
attack complex/perforin (MACPF) family of proteins has remained
ambiguous due to the technical challenges of working with these
proteins. The pore forming complement membrane attack complex
(MAC) and perforin deﬁne the MACPF protein family (reviewed in
[83,116]), but there are many members that are widespread among
both eukaryotes and prokaryotes [117]. The terminal pathway ofcomplement, the MAC, is assembled from C5b, C6, C7, C8 and C9
proteins. C8 and C9 are the major proteins that form the MAC pore.
This pathway is involved in the defense against invading Gram-
negative bacteria by the formation of pores in their membrane
[118]. Perforin is a major mediator of host cell destruction by natural
killer cells and CD8+ cytotoxic T-cells. Tumor cells, cells infected
with viruses or intracellular bacterial pathogens can be targeted for
destruction. Perforin forms pores in the host membrane, which can be
directly cytotoxic. It appears, however, that its major function may be
effect the delivery of granzymes to the cytosol of the targeted cells
to induce apoptosis [119]. Regardless of the mechanism by which
perforin effects cell killing the perforin pore is required.
The mechanism by which the MAC and perforin form pores in
the membrane has languished due to the difﬁculty of working with
these proteins and the difﬁculty in expressing functional recombinant
forms of these proteins. Recently, however, the crystal structures have
been solved for several members of the MACPF family of proteins.
These include complement protein C8 [120] and C8α [87,90], mouse
perforin [88] and a complement C9-like protein, pleurotolysin, from
the bacterium Photorhabdus luminescens [89]. The MACPF crystal
structures revealed that they contained a protein fold strikingly
similar to domain 3 of PFO (Fig. 3). The similarities of theMACPFswith
the CDCs and a description of the MACPF family of proteins have
been the subject of an excellent recent review by Rosado et al. [117].
This common protein fold, which is responsible for the formation of
the CDC pore [50,51], was found only in the CDCs prior to the solution
of the MACPF crystal structures. This revelation was a major break-
through in elucidating a potential pore forming mechanism for the
MACPF proteins. These investigators [87,89,90] suggested that like
the CDCs the MACPF proteins also unravel two α-helical bundles to
form two amphipathic β-hairpins that combine to form an oligomeric
β-barrel pore complex.
If the MACPF α-helical bundles do form extended transmembrane
β-hairpins like the CDCS then there is at least one obvious difference
in their structures when compared to the CDCs: the estimated length
of these hairpins is signiﬁcantly longer, inmost cases, than those found
in the CDCs. This suggests that these hairpins may be sufﬁciently long
to span the bilayerwithout a signiﬁcant collapse of a prepore structure,
as is found in the CDCs. Law et al. [88] recently proposed that the
putative hairpins ofmouse perforinwere sufﬁciently long to reach and
cross the membrane. In fact, they proposed that instead of extending
out on the same side of the perforin molecule they should extend to
the opposite side of the molecule. If true this would represent a
remarkable deviation from the CDC mechanism.
Are there any other features of the CDCs that suggest a functional
relationship with the MACPF proteins? No sequence homology exists
between the MACPF proteins and the CDCs, however, the double
glycine motif that exists in the loop that connects β4 and β5 in the
CDC domain 3 core β-sheet is also found in the MACPFs (Fig. 3). As
indicated above in Section 5, these two glycines are conserved in all
known CDC primary structures. They are also conspicuously present
in a similar location in the MACPFmonomer crystal structures (Fig. 3).
We have shown that this glycine pair cannot be changed in PFO to
residues with a sidechain without loss of pore forming activity [46].
If amino acids with sidechains are introduced at this location the
rotation of β5 away from β4 is prevented, presumably due to steric
clashes of the sidechains with nearby residues. As mentioned above
in Section 5, this rotation frees up the edge of β4 to pair with β1 of
another monomer. The presence of a glycine pair in a conserved
location in the MACPF crystal structures suggests that these residues
may also be necessary for the rotation of the MACPF structure that
is analogous to the CDC β5-α1 loop away from β4 [46] to allow the
intermolecular pairing of β1 and β4. Although it is compelling to
suggest a mechanism of pore formation for the MACPF protein family
based on the structural similarities with the CDCs, they must be
viewed with caution until they are rigorously demonstrated.
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As described in Section 4.3 the CDCs ILY, VLY and LLY initiate the
formation of the pore by binding to human CD59. Interestingly, the
primary function of CD59 on human cells is to inhibit the formation
of the complement MAC pore on the host cell membranes to prevent
their lysis during times of complement activation. Complement
activation during a Gram-negative bacterial infection results in the
deposition of the complement MAC onto the bacterial outer mem-
brane, thereby forming a pore in the outer membrane of the bacterial
cell. Activated complement MAC, however, can also cause collateral
damage to nearby host cells. In addition to CD59 host cells can express
a number of other proteins that antagonize complement assembly at
different stages (reviewed in [121]). CD59 is a GPI-anchored terminal
complement inhibitor that binds to MACPF proteins C8α and C9 and
inhibits the formation of the terminal MAC pore [122,123]. In contrast,
the CDCs ILY, VLY and LLY initiate formation of their pores on human
cells by binding to human CD59. Therefore, CD59 serves to initiate the
formation of the ILY, VLY and LLY pores whereas it inhibits the
formation of the complement MAC pore.
Prior to formation of the pore ILY remains bound to CD59 [39].
While bound to CD59 it blocks the site on CD59 that interacts with
complement proteins C8α and C9. Therefore, CD59 cannot inhibit
assembly of the MAC while ILY remains engaged with CD59 [39].
This results in the host cells being more prone to attack by their hosts
own complement system. This observation and prior studies [37]
suggested that both ILY and C8α and C9 bound to similar sites on
CD59. As discussed in Section 4.3 above, Wickham et al. recently
mapped the binding site for ILY on CD59. Interestingly, the binding
site for ILY exhibited a deep correspondence to the site on CD59 that
binds to C8α and C9 [80]. Most of the residues involved in the binding
site for the CDCswere also involved in its interactionwith C8α and C9.
As indicated above the ILY binding site for CD59 exhibits a consensus
motif of YXYX14RS that is not found in C8α or C9. In fact, neither
C8α nor C9 exhibits signiﬁcant similarity in their binding sites for
CD59 [122–125]. Therefore the MAC proteins and the CDCs bind to a
highly conserved site on CD59, yet their binding sites for human CD59
exhibit a remarkable lack of similarity [122,123].
8. Summary and future perspectives
The study of the CDC pore-forming mechanism has revealed new
paradigms of how the large CDC oligomeric pore complex is assembled.
The study of the CDCs has shown that they undergo signiﬁcant
secondary and tertiary structural changes in order to form the CDC
pore. Furthermore, the CDCs employ a novel cholesterol-binding motif
to recognize and bind cholesterol at the membrane surface. The study
of the CDC mechanism has also led to new insights into the possible
mechanism of pore formation for the large family of eukaryotic and
prokaryotic MACPF proteins and suggests that they may be ancient
ancestors of the CDCs.
Some major features of the CDC pore forming mechanism still
remain elusive. For instance, we do not yet understand how the CDCs
time the insertion of the large β-barrel pore. Evidence suggests
that this happens upon completion of the ring shaped complex, but
the nature of the mechanism that triggers/regulates the insertion
remains unknown. After insertion of the β-barrel the fate of the lipid
and any associated proteins from the lumen of the pore also remains
unknown. Do the CDCs speciﬁcally carve out sections of membrane
that reduces the level of speciﬁc membrane proteins that may
have important roles in cellular physiology or signaling? Over a
decade ago Caparon and colleagues revealed that the Streptococcus
pyogenes CDC, SLO, speciﬁcally translocated another secreted protein
from S. pyogenes, a NAD glycohydrolase enzyme (SPN), into human
keratinocytes in an actin-independent process [4]. Remarkably,
they recently showed that this translocation system functions in theabsence of pore formation by SLO by showing that the prepore locked
form of SLO translocates SPN as well or better than native SLO.
Revealing the basis of this transport system will likely reveal an
entirely new non-pore forming function for some CDCs. The study of
the MACPF proteins also promises to reveal new insights into how
they form a pore. Like the CDCs they may form a β-barrel pore from
the α-helical bundle-derived β-hairpins, but are other features of the
assembly of the CDC pore complex conserved in the MACPF proteins?
Future studies into these various problems will reveal new paradigms
that will likely change our understanding of this fascinating group of
toxins and provide new insights into the mechanism of other pore
forming proteins.
Acknowledgements
This work was supported by a grant (2R01AI037657) from the
National Institutes of Allergy and Infectious Diseases.
References
[1] D. Portnoy, P.S. Jacks, D. Hinrichs, The role of hemolysin for intracellular growth
of Listeria monocytogenes, J. Exp. Med. 167 (1988) 1459–1471.
[2] M.M. Awad, A.E. Bryant, D.L. Stevens, J.I. Rood, Virulence studies on chromo-
somal alpha-toxin and theta-toxin mutants constructed by allelic exchange
provide genetic evidence for the essential role of alpha-toxin in Clostridium
perfringens-mediated gas gangrene, Mol. Microbiol. 15 (1995) 191–202.
[3] D.M. Ellemor, R.N. Baird, M.M. Awad, R.L. Boyd, J.I. Rood, J.J. Emmins, Use of
genetically manipulated strains of Clostridium perfringens reveals that both
alpha-toxin and theta-toxin are required for vascular leukostasis to occur in
experimental gas gangrene, Infect. Immun. 67 (1999) 4902–4907.
[4] J.C. Madden, N. Ruiz, M. Caparon, Cytolysin-mediated translocation (CMT): a
functional equivalent of type III secretion in gram-positive bacteria, Cell 104 (2001)
143–152.
[5] N.O. Gekara, S. Weiss, Lipid rafts clustering and signalling by listeriolysin O,
Biochem. Soc. Trans. 32 (2004) 712–714.
[6] N.O. Gekara, K. Westphal, B. Ma, M. Rohde, L. Groebe, S. Weiss, The multiple
mechanisms of Ca2+ signalling by listeriolysin O, the cholesterol-dependent
cytolysin of Listeria monocytogenes, Cell. Microbiol. 9 (2007) 2008–2021.
[7] M.A. Hamon, E. Batsche, B. Regnault, T.N. Tham, S. Seveau, C. Muchardt, P.
Cossart, Histone modiﬁcations induced by a family of bacterial toxins, Proc. Natl.
Acad. Sci. U. S. A. 104 (2007) 13467–13472.
[8] F. Rose, S.A. Zeller, T. Chakraborty, E. Domann, T.Machleidt, M. Kronke,W. Seeger,
F. Grimminger, U. Sibelius, Human endothelial cell activation and mediator
release in response to Listeria monocytogenes virulence factors, Infect. Immun. 69
(2001) 897–905.
[9] S.J. Wadsworth, H. Goldﬁne, Mobilization of protein kinase C in macrophages
induced by Listeria monocytogenes affects its internalization and escape from the
phagosome, Infect. Immun. 70 (2002) 4650–4660.
[10] B.R. Andersen, J.L. Duncan, Activationof humanneutrophilmetabolismby streptolysin
O, J. Infect. Dis. 141 (1980) 680–685.
[11] R. Cockeran, H.C. Steel, T.J. Mitchell, C. Feldman, R. Anderson, Pneumolysin
potentiates production of prostaglandin E(2) and leukotriene B(4) by human
neutrophils, Infect. Immun. 69 (2001) 3494–3496.
[12] R. Cockeran, A.J. Theron, H.C. Steel, N.M. Matlola, T.J. Mitchell, C. Feldman, R.
Anderson, Proinﬂammatory interactions of pneumolysin with human neutro-
phils, J. Infect. Dis. 183 (2001) 604–611.
[13] H. Baba, I. Kawamura, C. Kohda, T. Nomura, Y. Ito, T. Kimoto, I.Watanabe, S. Ichiyama,
M. Mitsuyama, Induction of gamma interferon and nitric oxide by truncated
pneumolysin that lacks pore-forming activity, Infect. Immun. 70 (2002) 107–113.
[14] R. Cockeran, C. Durandt, C. Feldman, T.J. Mitchell, R. Anderson, Pneumolysin
activates the synthesis and release of interleukin-8 by human neutrophils in
vitro, J. Infect. Dis. 186 (2002) 562–565.
[15] H. Fickl, R. Cockeran, H.C. Steel, C. Feldman, G. Cowan, T.J. Mitchell, R. Anderson,
Pneumolysin-mediated activation of NFkappaB in human neutrophils is
antagonized by docosahexaenoic acid, Clin. Exp. Immunol. 140 (2005) 274–281.
[16] J. Bernatoniene, Q. Zhang, S. Dogan, T.J. Mitchell, J.C. Paton, A. Finn, Induction of
CC and CXC chemokines in human antigen-presenting dendritic cells by the
pneumococcal proteins pneumolysin and CbpA, and the role played by toll-like
receptor 4, NF-kappaB, and mitogen-activated protein kinases, J. Infect. Dis. 198
(2008) 1823–1833.
[17] A.E. Bryant, R. Bergstrom, G.A. Zimmerman, J.L. Salyer, H.R. Hill, R.K. Tweten, H.
Sato, D.L. Stevens, Clostridium perfringens invasiveness is enhanced by effects
of theta toxin upon PMNL structure and function: the roles of leukocytotoxicity
and expression of CD11/CD18 adherence glycoprotein, FEMS Immunol. Med.
Microbiol. 7 (1993) 321–336.
[18] D.L. Stevens, A.E. Bryant, Role of theta-toxin, a sulfhydryl-activated cytolysin, in the
pathogenesis of clostridial gas gangrene, Clin. Infect. Dis. 16 (1993) S195–S199.
[19] D.L. Stevens, J. Mitten, C. Henry, Effects of alpha and theta toxins from Clostridium
perfringens on human polymorphonuclear leukocytes, J. Infect. Dis. 156 (1987)
324–333.
1037E.M. Hotze, R.K. Tweten / Biochimica et Biophysica Acta 1818 (2012) 1028–1038[20] D.L. Stevens, B.E. Troyer, D.T. Merrick, J.E. Mitten, R.D. Olson, Lethal effects and
cardiovascular effects of puriﬁed alpha- and theta-toxins from Clostridium
perfringens, J. Infect. Dis. 157 (1988) 272–279.
[21] L.A. Kirkham, J.M. Jefferies, A.R. Kerr, Y. Jing, S.C. Clarke, A. Smith, T.J. Mitchell,
Identiﬁcation of invasive serotype 1 pneumococcal isolates that express
nonhemolytic pneumolysin, J. Clin. Microbiol. 44 (2006) 151–159.
[22] J.M. Jefferies, C.H. Johnston, L.A. Kirkham, G.J. Cowan, K.S. Ross, A. Smith, S.C.
Clarke, A.B. Brueggemann, R.C. George, B. Pichon, G. Pluschke, V. Pﬂuger, T.J.
Mitchell, Presence of nonhemolytic pneumolysin in serotypes of Streptococcus
pneumoniae associatedwith disease outbreaks, J. Infect. Dis. 196 (2007) 936–944.
[23] J.A. Walker, R.L. Allen, P. Falmagne, M.K. Johnson, G.J. Boulnois, Molecular
cloning, characterization, and complete nucleotide sequence of the gene for
pneumolysin, the sulfhydryl-activated toxin of Streptococcus pneumoniae, Infect.
Immun. 55 (1987) 1184–1189.
[24] M.A.Kehoe, L.Miller, J.A.Walker,G.J. Boulnois,Nucleotide sequenceof the streptolysin
O (SLO) gene: structural homologies between SLO and other membrane-damaging,
thiol-activated toxins, Infect. Immun. 55 (1987) 3228–3232.
[25] M.K. Johnson, Cellular location of pneumolysin, FEMS Microbiol. Lett. 2 (1977)
243–245.
[26] P. Balachandran, S.K. Hollingshead, J.C. Paton, D.E. Briles, The autolytic enzyme
LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin,
J. Bacteriol. 183 (2001) 3108–3116.
[27] K.E. Price, A. Camilli, Pneumolysin localizes to the cell wall of Streptococcus
pneumoniae, J. Bacteriol. 191 (2009) 2163–2168.
[28] S. Farrand, E. Hotze, P. Friese, S.K. Hollingshead, D.F. Smith, R.D. Cummings, G.L.
Dale, R.K. Tweten, Characterization of a streptococcal cholesterol-dependent
cytolysin with a Lewis y and b speciﬁc lectin domain, Biochemistry 47 (2008)
7097–7107.
[29] A.L. Decatur, D.A. Portnoy, A PEST-like sequence in listeriolysin O essential for
Listeria monocytogenes pathogenicity, Science 290 (2000) 992–995.
[30] P. Schnupf, J. Zhou, A. Varshavsky, D.A. Portnoy, Listeriolysin O secreted by
Listeria monocytogenes into the host cell cytosol is degraded by the N-end rule
pathway, Infect. Immun. 75 (2007) 5135–5147.
[31] M.A. Meehl, M.G. Caparon, Speciﬁcity of streptolysin O in cytolysin-mediated
translocation, Mol. Microbiol. 52 (2004) 1665–1676.
[32] J. Rossjohn, S.C. Feil, W.J. McKinstry, R.K. Tweten, M.W. Parker, Structure of a
cholesterol-binding thiol-activated cytolysin and a model of its membrane form,
Cell 89 (1997) 685–692.
[33] G. Polekhina, K.S. Giddings, R.K. Tweten, M.W. Parker, Insights into the action of
the superfamily of cholesterol-dependent cytolysins from studies of intermedi-
lysin, Proc. Natl. Acad. Sci. 102 (2005) 600–605.
[34] R.W. Bourdeau, E. Malito, A. Chenal, B.L. Bishop, M.W. Musch, M.L. Villereal, E.B.
Chang, E.M. Mosser, R.F. Rest, W.J. Tang, Cellular functions and X-ray structure of
anthrolysin O, a cholesterol-dependent cytolysin secreted by Bacillus anthracis,
J. Biol. Chem. 284 (2009) 14645–14656.
[35] L. Xu, B. Huang, H. Du, X.C. Zhang, J. Xu, X. Li, Z. Rao, Crystal structure of cytotoxin
protein suilysin from Streptococcus suis, Protein Cell 1 (2010) 96–105.
[36] M. Nakamura, N. Sekino, M. Iwamoto, Y. Ohno-Iwashita, Interaction of theta-
toxin (perfringolysin O), a cholesterol-binding cytolysin, with liposomal
membranes: change in the aromatic side chains upon binding and insertion,
Biochemistry 34 (1995) 6513–6520.
[37] K.S. Giddings, J. Zhao, P.J. Sims, R.K. Tweten, Human CD59 is a receptor for the
cholesterol-dependent cytolysin intermedilysin, Nat. Struct. Mol. Biol. 11 (2004)
1173–1178.
[38] S.E. Gelber, J.L. Aguilar, K.L. Lewis, A.J. Ratner, Functional and phylogenetic
characterization of vaginolysin, the human-speciﬁc cytolysin from Gardnerella
vaginalis, J. Bacteriol. 190 (2008) 3896–3903.
[39] S. LaChapelle, R.K. Tweten, E.M. Hotze, Intermedilysin-receptor interactions
during assembly of the pore complex: assembly intermediates increase host
cell susceptibility to complement-mediated lysis, J. Biol. Chem. 284 (2009)
12719–12726.
[40] A.J. Farrand, S. LaChapelle, E.M. Hotze, A.E. Johnson, R.K. Tweten, Only two amino
acids are essential for cytolytic toxin recognition of cholesterol at the membrane
surface, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 4341–4346.
[41] K.S. Giddings, A.E. Johnson, R.K. Tweten, Redeﬁning cholesterol's role in the
mechanism of the cholesterol-dependent cytolysins, Proc. Natl. Acad. Sci. U. S. A.
100 (2003) 11315–11320.
[42] R. Ramachandran, A.P. Heuck, R.K. Tweten, A.E. Johnson, Structural insights into
the membrane-anchoring mechanism of a cholesterol-dependent cytolysin, Nat.
Struct. Biol. 9 (2002) 823–827.
[43] A.P. Heuck, R.K. Tweten, A.E. Johnson, Assembly and topography of the prepore
complex in cholesterol-dependent cytolysins, J. Biol. Chem. 278 (2003)
31218–31225.
[44] R. Ramachandran, R.K. Tweten, A.E. Johnson, The domains of a cholesterol-
dependent cytolysin undergo a major FRET-detected rearrangement during pore
formation, Proc. Natl. Acad. Sci. 102 (2005) 7139–7144.
[45] D.M. Czajkowsky, E.M. Hotze, Z. Shao, R.K. Tweten, Vertical collapse of a cytolysin
prepore moves its transmembrane β-hairpins to the membrane, EMBO J. 23
(2004) 3206–3215.
[46] R. Ramachandran, R.K. Tweten, A.E. Johnson, Membrane-dependent conforma-
tional changes initiate cholesterol-dependent cytolysin oligomerization and
intersubunit β-strand alignment, Nat. Struct. Mol. Biol. 11 (2004) 697–705.
[47] E.M. Hotze, A.P. Heuck, D.M. Czajkowsky, Z. Shao, A.E. Johnson, R.K. Tweten,
Monomer–monomer interactions drive the prepore to pore conversion of a beta-
barrel-forming cholesterol-dependent cytolysin, J. Biol. Chem. 277 (2002)
11597–11605.[48] E.M. Hotze, E.M. Wilson-Kubalek, J. Rossjohn, M.W. Parker, A.E. Johnson, R.K.
Tweten, Arresting pore formation of a cholesterol-dependent cytolysin by
disulﬁde trapping synchronizes the insertion of the transmembrane beta-sheet
from a prepore intermediate, J. Biol. Chem. 276 (2001) 8261–8268.
[49] L.A. Shepard, O. Shatursky, A.E. Johnson, R.K. Tweten, The mechanism of
assembly and insertion of the membrane complex of the cholesterol-dependent
cytolysin perfringolysin O: formation of a large prepore complex, Biochemistry
39 (2000) 10284–10293.
[50] O. Shatursky, A.P. Heuck, L.A. Shepard, J. Rossjohn, M.W. Parker, A.E. Johnson, R.K.
Tweten, The mechanism of membrane insertion for a cholesterol dependent
cytolysin: a novel paradigm for pore-forming toxins, Cell 99 (1999) 293–299.
[51] L.A. Shepard, A.P. Heuck, B.D. Hamman, J. Rossjohn, M.W. Parker, K.R. Ryan, A.E.
Johnson, R.K. Tweten, Identiﬁcation of a membrane-spanning domain of the
thiol-activated pore-forming toxin Clostridium perfringens perfringolysin O: an
α-helical to β-sheet transition identiﬁed by ﬂuorescence spectroscopy, Bio-
chemistry 37 (1998) 14563–14574.
[52] J.E. Alouf, Cholesterol-binding cytolytic protein toxins, Int. J. Med. Microbiol. 290
(2000) 351–356.
[53] D. Prigent, J.E. Alouf, Interaction of streptolysin Owith sterols, Biochem. Biophys.
Acta 433 (1976) 422–428.
[54] M.K. Johnson, C. Geoffroy, J.E. Alouf, Binding of cholesterol by sulfhydryl-
activated cytolysins, Infect. Immun. 27 (1980) 97–101.
[55] M. Iwamoto, Y. Ohno-Iwashita, S. Ando, Role of the essential thiol group in the
thiol-activated cytolysin from Clostridium perfringens, Eur. J. Biochem. 167
(1987) 425–430.
[56] I. Nagy, Y. Ohno-Iwashita, M. Ohta, V. Nagy, K. Kitani, S. Ando, K. Imahori, Effect of
perfringolysin O on the lateral diffusion constant of membrane proteins of
hepatocytes as revealed by ﬂuorescence recovery after photobleaching, Biochim.
Biophys. Acta 939 (1988) 551–560.
[57] Y. Ohno-Iwashita, M. Iwamoto, K. Mitsui, S. Ando, Y. Nagai, Protease nicked θ-
toxin of Clostridium perfringens, a new membrane probe with no cytolytic effect,
reveals two classes of cholesterol as toxin-binding sites on sheep erythrocytes,
Eur. J. Biochem. 176 (1988) 95–101.
[58] Y. Ohno-Iwashita, M. Iwamoto, S. Ando, K. Mitsui, S. Iwashita, A modiﬁed q-toxin
produced by limited proteolysis and methylation: a probe for the functional
study of membrane cholesterol, Biochim. Biophys. Acta 1023 (1990) 441–448.
[59] Y. Ohno-Iwashita, M. Iwamoto, K. Mitsui, S. Ando, S. Iwashita, A cytolysin, theta-
toxin, preferentially binds to membrane cholesterol surrounded by phospho-
lipids with 18-carbon hydrocarbon chains in cholesterol-rich region, J. Biochem.
(Tokyo) 110 (1991) 369–375.
[60] Y. Ohno-Iwashita, M. Iwamoto, S. Ando, S. Iwashita, Effect of lipidic factors on
membrane cholesterol topology-mode of binding of theta-toxin to cholesterol in
liposomes, Biochim. Biophys. Acta 1109 (1992) 81–90.
[61] M. Iwamoto, M. Nakamura, K. Mitsui, S. Ando, Y. Ohno-Iwashita, Membrane
disorganization induced by perfringolysin O (theta-toxin) of Clostridium
perfringens — effect of toxin binding and self-assembly on liposomes, Biochim.
Biophys. Acta 1153 (1993) 89–96.
[62] N. Sekino-Suzuki, M. Nakamura, K.I. Mitsui, Y. Ohno-Iwashita, Contribution of
individual tryptophan residues to the structure and activity of theta-toxin
(perfringolysin o), a cholesterol-binding cytolysin, Eur. J. Biochem. 241 (1996)
941–947.
[63] M. Iwamoto, I. Morita, M. Fukuda, S. Murota, S. Ando, Y. Ohno-Iwashita, A
biotinylated perfringolysin O derivative: a new probe for detection of cell surface
cholesterol, Biochim. Biophys. Acta 1327 (1997) 222–230.
[64] M. Nakamura, N. Sekino-Suzuki, K. Mitsui, Y. Ohno-Iwashita, Contribution of
tryptophan residues to the structural changes in perfringolysin O during
interaction with liposomal membranes, J. Biochem. (Tokyo) 123 (1998)
1145–1155.
[65] T. Jacobs, M.D. Cima-Cabal, A. Darji, F.J. Mendez, F. Vazquez, A.A. Jacobs, Y. Shimada,
Y. Ohno-Iwashita, S. Weiss, J.R. de los Toyos, The conserved undecapeptide shared
by thiol-activated cytolysins is involved in membrane binding, FEBS Lett. 459
(1999) 463–466.
[66] A.A. Waheed, Y. Shimada, H.F. Heijnen, M. Nakamura, M. Inomata, M. Hayashi, S.
Iwashita, J.W. Slot, Y. Ohno-Iwashita, Selective binding of perfringolysin O
derivative to cholesterol-rich membrane microdomains (rafts), Proc. Natl. Acad.
Sci. U. S. A. 98 (2001) 4926–4931.
[67] Y. Shimada, M. Maruya, S. Iwashita, Y. Ohno-Iwashita, The C-terminal domain of
perfringolysin O is an essential cholesterol-binding unit targeting to cholesterol-
rich microdomains, Eur. J. Biochem. 269 (2002) 6195–6203.
[68] Y. Ohno-Iwashita, M. Iwamoto, K. Mitsui, S. Ando, Y. Nagai, Protease-nicked
theta-toxin of Clostridium perfringens, a new membrane probe with no cytolytic
effect, reveals two classes of cholesterol as toxin-binding sites on sheep
erythrocytes, Eur. J. Biochem. 176 (1988) 95–101.
[69] A.P. Heuck, E. Hotze, R.K. Tweten, A.E. Johnson, Mechanism of membrane
insertion of a multimeric b-barrel protein: perfringolysin O creates a pore using
ordered and coupled conformational changes, Mol. Cell 6 (2000) 1233–1242.
[70] J.J. Flanagan, R.K. Tweten, A.E. Johnson, A.P. Heuck, Cholesterol exposure at the
membrane surface is necessary and sufﬁcient to trigger perfringolysin O binding,
Biochemistry 48 (2009) 3977–3987.
[71] S. Rottem, R.M. Cole, W.H. Habig, M.F. Barile, M.C. Hardegree, Structural
characteristics of tetanolysin and its binding to lipid vesicles, J. Bacteriol. 152
(1982) 888–892.
[72] L.D. Nelson, A.E. Johnson, E. London, How interaction of perfringolysin O with
membranes is controlled by sterol structure, lipid structure, and physiological
low pH: insights into the origin of perfringolysin O-lipid raft interaction, J. Biol.
Chem. 283 (2008) 4632–4642.
1038 E.M. Hotze, R.K. Tweten / Biochimica et Biophysica Acta 1818 (2012) 1028–1038[73] A. Zitzer, E.J. Westover, D.F. Covey, M. Palmer, Differential interaction of the two
cholesterol-dependent, membrane-damaging toxins, streptolysin O and Vibrio
cholerae cytolysin,with enantiomeric cholesterol, FEBS Lett. 553 (2003) 229–231.
[74] M. Iwamoto, Y. Ohno-Iwashita, S. Ando, Effect of isolated C-terminal fragment
of theta-toxin (perfringolysin-O) on toxin assembly and membrane lysis, Eur. J.
Biochem. 194 (1990) 25–31.
[75] Y. Shimada, M. Nakamura, Y. Naito, K. Nomura, Y. Ohno-Iwashita, C-terminal
amino acid residues are required for the folding and cholesterol binding
property of perfringolysin O, a pore-forming cytolysin, J. Biol. Chem. 274 (1999)
18536–18542.
[76] R.K. Tweten, R.W. Harris, P.J. Sims, Isolation of a tryptic fragment from
Clostridium perfringens q-toxin that contains sites for membrane binding and
self-aggregation, J. Biol. Chem. 266 (1991) 12449–12454.
[77] C.E. Soltani, E.M. Hotze, A.E. Johnson, R.K. Tweten, Speciﬁc protein-membrane
contacts are required for prepore and pore assembly by a cholesterol-dependent
cytolysin, J. Biol. Chem. 282 (2007) 15709–15716.
[78] C.E. Soltani, E.M. Hotze, A.E. Johnson, R.K. Tweten, Structural elements of the
cholesterol-dependent cytolysins that are responsible for their cholesterol-sensitive
membrane interactions, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 20226–20231.
[79] H. Nagamune, C. Ohnishi, A. Katsuura, K. Fushitani, R.A. Whiley, A. Tsuji, Y.
Matsuda, Intermedilysin, a novel cytotoxin speciﬁc for human cells secreted by
Streptococcus intermedius UNS46 isolated from a human liver abscess, Infect.
Immun. 64 (1996) 3093–3100.
[80] S.E. Wickham, E.M. Hotze, A.J. Farrand, G. Polekhina, T.L. Nero, S. Tomlinson,
M.W. Parker, R.K. Tweten, Mapping the intermedilysin-human CD59 receptor
interface reveals a deep correspondence with the binding site on CD59 for
complement binding proteins C8{alpha} and C9, J. Biol. Chem. 286 (2011)
20952–20962.
[81] S.A. Rollins, P.J. Sims, The complement-inhibitory activity of CD59 resides in its
capacity to block incorporation of C9 into membrane C5b-9, J. Immunol. 144
(1990) 3478–3483.
[82] S.A.Rollins, J. Zhao,H.Ninomiya, P.J. Sims, Inhibitionofhomologouscomplementby
CD59 is mediated by a species-selective recognition conferred through binding to
C8 within C5b-8 or C9 within C5b-9, J. Immunol. 146 (1991) 2345–2351.
[83] M.E. Plumb, J.M. Sodetz, Proteins of the membrane attack complex, in: J.E.
Volanakis, M.M. Frank (Eds.), The Human Complement System in Health and
Disease, vol. 1, Marcel Dekker, Inc., New York, 1998, pp. 119–148.
[84] M. Palmer, R. Harris, C. Freytag, M. Kehoe, J. Tranum-Jensen, S. Bhakdi, Assembly
mechanism of the oligomeric streptolysin O pore: the early membrane lesion is
lined by a free edge of the lipid membrane and is extended gradually during
oligomerization, EMBO J. 17 (1998) 1598–1605.
[85] S.H. White, W.C. Wimley, Membrane protein folding and stability: physical
principles, Annu. Rev. Biophys. Biomol. Struct. 28 (1999) 319–365.
[86] S.C. Feil, J. Rossjohn, K. Rohde, R.K. Tweten, M.W. Parker, Crystallization and
preliminary X-ray analysis of a thiol-activated cytolysin, FEBS Lett. 397 (1996)
290–292.
[87] M.A. Hadders, D.X. Beringer, P. Gros, Structure of C8alpha-MACPF reveals
mechanism of membrane attack in complement immune defense, Science 317
(2007) 1552–1554.
[88] R.H. Law, N. Lukoyanova, I. Voskoboinik, T.T. Caradoc-Davies, K. Baran, M.A.
Dunstone, M.E. D'Angelo, E.V. Orlova, F. Coulibaly, S. Verschoor, K.A. Browne, A.
Ciccone,M.J. Kuiper, P.I. Bird, J.A. Trapani, H.R. Saibil, J.C.Whisstock, The structural
basis for membrane binding and pore formation by lymphocyte perforin, Nature
468 (2010) 447–451.
[89] C.J. Rosado, A.M. Buckle, R.H. Law, R.E. Butcher, W.T. Kan, C.H. Bird, K. Ung, K.A.
Browne, K. Baran, T.A. Bashtannyk-Puhalovich, N.G. Faux, W. Wong, C.J. Porter,
R.N. Pike, A.M. Ellisdon, M.C. Pearce, S.P. Bottomley, J. Emsley, A.I. Smith, J.
Rossjohn, E.L. Hartland, I. Voskoboinik, J.A. Trapani, P.I. Bird, M.A. Dunstone, J.C.
Whisstock, A common fold mediates vertebrate defense and bacterial attack,
Science 317 (2007) 1548–1551.
[90] D.J. Slade, L.L. Lovelace, M. Chruszcz, W. Minor, L. Lebioda, J.M. Sodetz, Crystal
structure of the MACPF domain of human complement protein C8 alpha in
complex with the C8 gamma subunit, J. Mol. Biol. 379 (2008) 331–342.
[91] M. Palmer, P. Saweljew, I. Vulicevic, A. Valeva, M. Kehoe, S. Bhakdi, Membrane-
penetrating domain of streptolysin O identiﬁed by cysteine scanning mutagen-
esis, J. Biol. Chem. 271 (1996) 26664–26667.
[92] K. Sekiya, R. Satoh, H. Danbara, Y. Futaesaku, A ring-shaped structure with a crown
formed by streptolysin-O on the erythrocyte membrane, J. Bacteriol. 175 (1993)
5953–5961.
[93] K.Mitsui, T. Sekiya, S. Okamura, Y. Nozawa, J. Hase, Ring formation of perfringolysin
O as revealed by negative stain electron microscopy, Biochim. Biophys. Acta 558
(1979) 307–313.
[94] T. Jacobs, A. Darji, N. Frahm, M. Rohde, J. Wehland, T. Chakraborty, S. Weiss,
ListeriolysinO: cholesterol inhibits cytolysis but not binding to cellularmembranes,
Mol. Microbiol. 28 (1998) 1081–1089.
[95] J. Rossjohn, G. Polekhina, S.C. Feil, C.J. Morton, R.K. Tweten, M.W. Parker,
Structures of perfringolysin O suggest a pathway for activation of cholesterol-
dependent cytolysins, J. Mol. Biol. 367 (2007) 1227-1223.
[96] S.J. Tilley, E.V. Orlova, R.J. Gilbert, P.W. Andrew, H.R. Saibil, Structural basis of
pore formation by the bacterial toxin pneumolysin, Cell 121 (2005) 247–256.[97] C. Geoffroy, J.L. Gaillard, J.E. Alouf, P. Berche, Puriﬁcation, characterization,
and toxicity of the sulfhydryl-activated hemolysin listeriolysin O from Listeria
monocytogenes, Infect. Immun. 55 (1987) 1641–1646.
[98] P. Cossart, Molecular and cellular basis of the infection by Listeria monocytogenes:
an overview, Int. J. Med. Microbiol. 291 (2002) 401–409.
[99] D.A. Portnoy, V. Auerbuch, I.J. Glomski, The cell biology of Listeria monocytogenes
infection: the intersection of bacterial pathogenesis and cell-mediated immu-
nity, J. Cell Biol. 158 (2002) 409–414.
[100] S. Kayal, A. Charbit, Listeriolysin O: a key protein of Listeria monocytogenes with
multiple functions, FEMS Microbiol. Rev. 30 (2006) 514–529.
[101] J. Bielecki, P. Youngman, P. Connelly, D.A. Portnoy, Bacillus subtilis expressing a
haemolysin gene from Listeria monocytogenes can grow in mammalian cells,
Nature 345 (1990) 175–176.
[102] D.A. Portnoy, R.K. Tweten, M. Kehoe, J. Bielecki, The capacity of listeriolysin O,
streptolysin O and perfringolysin O to mediate growth of Bacillus subtilis within
mammalian cells, Infect. Immun. 60 (1992) 2710–2717.
[103] S. Jones, D.A. Portnoy, Characterization of Listeria monocytogenes pathogenesis in
a strain expressing perfringolysin O in place of listeriolysin O, Infect. Immun. 62
(1994) 5608–5613.
[104] R.K. Draper, M.I. Simon, The entry of diphtheria toxin into the mammalian cell
cytoplasm: evidence for lysosomal involvement, J. Cell Biol. 87 (1980) 849–854.
[105] K. Sandvig, S. Olsnes, Diphtheria toxin entry into cells is facilitated by low pH, J.
Cell Biol. 87 (1980) 828–832.
[106] J.J. Donovan, M.I. Simon, R.K. Draper, M. Montal, Diphtheria toxin forms
transmembrane channels in planar lipid bilayers, Proc. Natl. Acad. Sci. U. S. A.
78 (1981) 172–176.
[107] R.B. Dorland, J.L. Middlebrook, S.H. Leppla, Effect of ammonium chloride on
receptor-mediated uptake of diphtheria toxin by Vero cells, Exp. Cell Res. 134
(1981) 319–327.
[108] B.L. Kagan, A. Finkelstein, M. Colombini, Diphtheria toxin fragment forms large
pores in phospholipid bilayer membranes, Proc. Nat. Acad. Sci. U. S. A. 78 (1981)
4950–4954.
[109] M.G. Blewitt, L.A. Chung, E. London, Effect of pH on the conformation of
diphtheria toxin and its implications for membrane penetration, Biochemistry
24 (1985) 5458–5464.
[110] R.J. Collier, Mechanism of membrane translocation by anthrax toxin: insertion
and pore formation by protective antigen, J. Appl. Microbiol. 87 (1999) 283.
[111] D.W. Schuerch, E.M. Wilson-Kubalek, R.K. Tweten, Molecular basis of lister-
iolysin O pH-dependence, Proc. Natl. Acad. Sci. 102 (2005) 12537–12542.
[112] J.A. Morrill, R. MacKinnon, Isolation of a single carboxyl-carboxylate proton
binding site in the pore of a cyclic nucleotide-gated channel, J. Gen. Physiol. 114
(1999) 71–83.
[113] K. Tozawa, H. Ohbuchi, H. Yagi, T. Amano, T.Matsui, M. Yoshida, H. Akutsu, Unusual
pKa of the carboxylate at the putative catalytic position of the thermophilic F1-
ATPase beta subunit determined by 13C NMR, FEBS Lett. 397 (1996) 122–126.
[114] S. Kawaminami, H. Takahashi, S. Ito, Y. Arata, I. Shimada, A multinuclear NMR
study of the active site of an endoglucanase from a strain of Bacillus. Use of Trp
residues as structural probes, J. Biol. Chem. 274 (1999) 19823–19828.
[115] J. Davoodi, W.W.Wakarchuk, R.L. Campbell, P.R. Carey,W.K. Surewicz, Abnormally
high pKa of an active-site glutamic acid residue in Bacillus circulans xylanase. The
role of electrostatic interactions, Eur. J. Biochem. 232 (1995) 839–843.
[116] I. Voskoboinik, M.J. Smyth, J.A. Trapani, Perforin-mediated target-cell death and
immune homeostasis, Nat. Rev. Immunol. 6 (2006) 940–952.
[117] C.J. Rosado, S. Kondos, T.E. Bull, M.J. Kuiper, R.H. Law, A.M. Buckle, I. Voskoboinik,
P.I. Bird, J.A. Trapani, J.C. Whisstock, M.A. Dunstone, The MACPF/CDC family of
pore-forming toxins, Cell. Microbiol. 10 (2008) 1765–1774.
[118] A.F. Esser, The membrane attack complex of complement. Assembly, structure
and cytotoxic activity, Toxicology 87 (1994) 229–247.
[119] K. Baran, M. Dunstone, J. Chia, A. Ciccone, K.A. Browne, C.J. Clarke, N. Lukoyanova,
H. Saibil, J.C. Whisstock, I. Voskoboinik, J.A. Trapani, The molecular basis for
perforin oligomerization and transmembrane pore assembly, Immunity 30
(2009) 684–695.
[120] L.L. Lovelace, C.L. Cooper, J.M. Sodetz, L. Lebioda, Structure of human C8 protein
provides mechanistic insight into membrane pore formation by complement,
J. Biol. Chem. 286 (2011) 17585–17592.
[121] D.D. Kim,W.C. Song, Membrane complement regulatory proteins, Clin. Immunol.
118 (2006) 127–136.
[122] Y. Huang, F. Qiao, R. Abagyan, S. Hazard, S. Tomlinson, Deﬁning the CD59-C9
binding interaction, J. Biol. Chem. 281 (2006) 27398–27404.
[123] D.H. Lockert, K.M. Kaufman, C.P. Chang, T. Husler, J.M. Sodetz, P.J. Sims, Identity
of the segment of human complement C8 recognized by complement regulatory
protein CD59, J. Biol. Chem. 270 (1995) 19723–19728.
[124] C.P. Chang, T. Husler, J. Zhao, T. Wiedmer, P.J. Sims, Identity of a peptide domain
of human C9 that is bound by the cell-surface complement inhibitor, CD59,
J. Biol. Chem. 269 (1994) 26424–26430.
[125] T. Husler, D.H. Lockert, K.M. Kaufman, J.M. Sodetz, P.J. Sims, Chimeras of human
complement C9 reveal the site recognized by complement regulatory protein
CD59, J. Biol. Chem. 270 (1995) 3483–3486.
[126] W. Humphrey, A. Dalke, K. Schulten, VMD: visual molecular dynamics, J. Mol.
Graph. 14 (1996) 33–38 27–38.
